Association of KCNJ2 Genetic Variants with Susceptibility to Thyrotoxic Periodic Paralysis in Patients with Graves’ Disease

Abstract

Objective: Thyrotoxic periodic paralysis (TPP) is characterized by acute onset paralysis and hypokalemia predominantly in male patients with thyrotoxicosis. Recent studies have emphasized the importance of potassium channels, which might explain the underlying mechanism of TPP. The KCNJ2 gene encodes the inward-rectifying potassium channel. In this study, we evaluated the role of KCNJ2 in the development of TPP.

Design: Case-control analysis of KCNJ2 genetic association with TPP.

Patients: 83 male patients with Graves’ disease (GD) were recruited for this study; 43 patients had TPP, whereas 40 patients had no history of TPP.

Measurements: We analyzed the genotype and allelic frequency of a single-nucleotide polymorphism (SNP; rs312691) (C>T) adjacent to the KCNJ2 gene that is known to be related to TPP development.

Results: The frequency of the CC genotype of the rs312691 SNP was 0.51 in TPP patients and 0.05 in controls (p-value=6.18×10⁻⁶). The C allele frequency of the SNP was 0.67 in the TPP group and 0.38 in the control group (odds ratio 3.24; 95% confidence interval 1.65–6.51; p-value, 3.1×10⁻⁴). The rs312691 SNP was significantly associated with TPP.

Conclusions: We demonstrated that the rs312691 SNP was significantly associated with TPP. These findings suggest that KCNJ2 plays an important role in the pathophysiology of TPP in Korean GD patients with TPP.

• References

• 1 Maciel RMB, Lindsey SC, da Silva MRD. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 2011; 7: 657-667
• 2 Kung AWC. Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 2006; 91: 2490-2495
• 3 Ober KP. Thyrotoxic Periodic Paralysis in the United States Report of 7 Cases and Review of the Literature. Medicine 1992; 71: 109-120
• 4 Cheung C-L, Lau K-S, Ho AY et al. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24. 3. Nat Genet 2012; 44: 1026-1029
• 5 Ryan DP, da Silva MR, Soong TW et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010; 140: 88-98
• 6 Lapie P, Lory P, Fontaine B. Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. Neuromuscul Disord 1997; 7: 234-240
• 7 Chen L, Lang D, Ran XW et al. Clinical and molecular analysis of chinese patients with thyrotoxic periodic paralysis. Eur Neurol 2002; 49: 227-230
• 8 Phakdeekitcharoen B, Ruangraksa C, Radinahamed P. Hypokalaemia and paralysis in the Thai population. Nephrology Dialysis Transplantation 2004; 19: 2013-2018
• 9 Ng WY, Lui KF, Thai AC et al. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid 2004; 14: 187-190
• 10 Kung AWC, Lau KS, Fong GCY et al. Association of novel single nucleotide polymorphisms in the calcium channel α1 subunit gene (Cav1. 1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab 2004; 89: 1340-1345
• 11 Dias Da Silva MR, Cerutti JM, Arnaldi LAT et al. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab 2002; 87: 4881-4884
• 12 Jongjaroenprasert W, Phusantisampan T, Mahasirimongkol S et al. A genome-wide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemic periodic paralysis. J Hum Genet 2012; 57: 301-304
• 13 Wang X, Chow CC, Yao X et al. The predisposition to thyrotoxic periodic paralysis (TPP) is due to a genetic variant in the inward-rectifying potassium channel, KCNJ2. Clin Endocrinol (Oxf) 2014; 80: 770-771
• 14 Park S, Kim TY, Sim S et al. Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves' Disease. Endocrinol Metab (Seoul) 2016; 31: 142-146
• 15 Kim WB, Han SM, Kim TY et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60: 719-725
• 16 Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361-372
• 17 Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999; 159: 601-606
• 18 Abbasi B, Sharif Z, Sprabery LR. Hypokalemic thyrotoxic periodic paralysis with thyrotoxic psychosis and hypercapnic respiratory failure. Am J Med Sci 2010; 340: 147-153
• 19 Lam KSL, Yeung RTT, Benson EA et al. Erythrocyte sodium-potassium pump in thyrotoxic periodic paralysis. Aust N Z J Med 1989; 19: 6-10
• 20 Chan A, Shinde R, Chow CC et al. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991; 303: 1096-1099
• 21 Desai-Yajnik V, Zeng J, Omori K et al. The effect of thyroid hormone treatment on the gene expression and enzyme activity of rat liver sodium-potassium dependent adenosine triphosphatase. Endocrinology 1995; 136: 629-639
• 22 Hundal HS, Marette A, Mitsumoto Y et al. Insulin induces translocation of the alpha 2 and beta 1 subunits of the Na+/K (+)-ATPase from intracellular compartments to the plasma membrane in mammalian skeletal muscle. J Biol Chem 1992; 267: 5040-5043
• 23 Pothiwala P, Levine SN. Analytic review: thyrotoxic periodic paralysis: a review. J Intensive Care Med 2010; 25: 71-77
• 24 Meikle AW. The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid 2004; 14: 17-25
• 25 Hsieh MJ, Lyu RK, Chang WN et al. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol 2008; 15: 559-564